跳到正文

Baker Bros. Advisors LP 13F 持仓 · 2026年Q2

Baker Bros. Advisors 在 2026年Q2(报告期截至 2026-06-30)的 SEC 13F 申报中报告了 83 只证券,申报市值合计 199.55 亿美元。前几大持仓:INCY(17.48%)、ONC(12.57%)、RVMD(10.74%)。本季前 25 大持仓中:增持 9 只、减持 4 只。

排名代码公司市值占组合股数变动
1INCYIncyte Corporation$3.49B17.48%30.8M增持
2ONCBeOne Medicines Ltd.$2.51B12.57%8.8M增持
3RVMDRevolution Medicines, Inc.$2.14B10.74%11.4M增持
4MDGLMadrigal Pharmaceuticals, Inc.$1.15B5.77%2.1M增持
5ACADACADIA Pharmaceuticals Inc.$1.09B5.44%42.9M增持
6KYMRKymera Therapeutics, Inc.$992.7M4.97%8.7M持平
7INSMInsmed Incorporated$937.8M4.70%8.8M增持
8CELCCelcuity Inc.$828.2M4.15%7.9M持平
9KODKodiak Sciences Inc.$776.1M3.89%19.9M持平
10RYTMRhythm Pharmaceuticals, Inc.$622.3M3.12%5.6M持平
11PRAXPraxis Precision Medicines, Inc.$587.0M2.94%1.8M持平
12ALKSAlkermes plc$524.6M2.63%10.0M持平
13SMMTSummit Therapeutics Inc.$477.7M2.39%32.8M减持
14GRALGRAIL, Inc.$275.0M1.38%4.0M持平
15ABCLAbCellera Biologics Inc.$259.1M1.30%33.0M增持
16IMVTImmunovant, Inc.$209.4M1.05%5.4M减持
17IDYAIDEAYA Biosciences, Inc.$186.7M0.94%5.0M增持
18KNSAKiniksa Pharmaceuticals International, plc$181.3M0.91%2.8M增持
19ROIVRoivant Sciences Ltd.$166.9M0.84%4.7M减持
20ARWRArrowhead Pharmaceuticals, Inc.$162.4M0.81%2.0M持平
21IONSIonis Pharmaceuticals, Inc.$162.4M0.81%2.0M持平
22EWTXEdgewise Therapeutics, Inc.$150.4M0.75%3.7M减持
23REPLReplimune Group, Inc.$122.3M0.61%11.0M持平
24NRIXNurix Therapeutics, Inc.$113.0M0.57%4.7M持平
25STOKStoke Therapeutics, Inc.$109.2M0.55%3.3M持平

来源:SEC 13F 申报文件 · 截至 2026-06-30

本期 13F-HR 中的全部持仓,以及相对上季度的变化。

13F 持仓,最新季度

来源SEC EDGAR13F-HR